New data from Precedence Research highlights the current state of the tissue engineering market. The sector is led by major medtech companies like Integra LifeSciences and Vericel which are generating significant revenue from artificial skin and bone scaffolds. Integra is doing about $1.6B and Vericel is over $600M. Zimmer Biomet and Medtronic are also heavily involved in the orthopedic side. Smaller companies like Organovo and BICO are focused on 3D bioprinting and bio-inks but are still in early revenue stages. The report also notes continued government support, with recent NIH grants going toward dental and tissue repair research.